Basic Information
Lutathera
Regulatory Information
EMEA/H/C/004123
September 26, 2017
July 20, 2017
16
April 3, 2025
Company Information
France
Advanced Accelerator Applications 8-10 Rue Henri Sainte-Claire Deville 92500 Rueil-Malmaison
ADVANCED ACCELERATOR APPLICATIONS
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP?NETs) in adults.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Lutathera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Lutathera. For practical information about using Lutathera, patients should read the package leaflet or contact their doctor or pharmacist.